19 hrs ago
WTSP-TV Saint Petersburg
FDA approves magnetic device to treat migraine
SAINT PAUL, Minnesota - Millions of people suffer from migraines every year. While there's no known cure, there's a new drug-free treatment on the market.
20 hrs ago
The Motley Fool
A Pain Specialist Buys a Technology Call Option
While prior management didn't do well with its M&A, new management has already made some smart deals for Paladin Labs and Boca Pharmaceutical.
The Motley Fool
Zogenix: 3 Key Investing Takeaways From 2013
The company scored a major victory in October when the FDA However, that victory was a highly controversial one, since Zohydro ER is five to ten times more potent than Vicodin, which is a comparatively milder mix of hydrocodone and the non-narcotic painkiller acetaminophen.
Depomed snaps up Nautilus migraine drug for $48.7M
Completing its second Indian deal this quarter, Pieris AG entered a pact with Stelis Biopharma Pvt.
Wed Dec 18, 2013
MultiCorp International, Inc. /XTend Medical Acquires 70% Ownership...
MultiCorp International, Inc, has acquired a 70% stake in a patented migraine medication.
Tue Dec 17, 2013
FDA Approves First Device to Relieve Migraine Pain
The FDA has approved the Cerena Transcranial Magnetic Stimulator , the first device to relieve pain caused by migraine headaches that are preceded by an aura .
Depomed Acquires CAMBIAA (Diclofenac Potassium for Oral Solution)...
Depomed, Inc. today announced that it has acquired the United States rights to CAMBIA from Nautilus Neurosciences for $48.7 million.
Path Shareholder Alert: The Law Firm of Wohl & Fruchter is...
The law firm of Wohl & Fruchter LLP is investigating the acquisition of NuPathe, Inc. by Endo Health Solutions Inc. .
Mon Dec 16, 2013
Kansas City InfoZine
Migraine Headache Pain Relief Gets Help
Migraine headaches are characterized by intense pulsing or throbbing pain in one area of the head accompanied by nausea and/or vomiting and sensitivity to light and sound.
Endo Health to acquire Nupathe for $105 million
Specialty pharmaceutical company Endo Health Solutions Inc said it would buy NuPathe Inc for about $105 million to gain access to NuPathe's migraine treatment, Zecuity.
Sun Dec 15, 2013
FDA Approves New Magnet Device to Treat Migraines
SUNDAY Dec. 15, 2013, 2013 -- The U.S. Food and Drug Administration has approved the first device aimed at easing the pain of migraines preceded by aura -- sensory disturbances that occur just before an attack.
Fri Dec 13, 2013
Inland Empire Weekly
I had never experienced a true migraine when, in 1998, I first saw the movie , Darren Aronofsky's celebrated indie flick about a genius mathematician who goes to extreme levels to stop the misery incurred by his chronic migraines.
FDA Allows Marketing of First Device to Relieve Migraine Headache Pain
December 13, 2013 -- The U.S. Food and Drug Administration today allowed marketing of the Cerena Transcranial Magnetic Stimulator , the first device to relieve pain caused by migraine headaches that are preceded by an aura: a visual, sensory or motor disturbance immediately preceding the onset of a migraine attack.
Wed Dec 11, 2013
NuPathe Takes Investors Down A Bumpy Road
Three years ago, there were high hopes for NuPathe Inc. , a specialty pharmaceutical company that develops therapeutics for neurological and psychiatric disorders.
WHO-TV Des Moines
Livewell Minute: Migraine Headaches
Migraine headache affects 36 million Americans. Migrane attacks may last from 4 hours to 3 days, with sufferers experiencing pounding head pain, nausea and sensitivity to sound and light.
The Ten Biggest Medical Successes of 2013
1. The Long Term Success of a Gene Patch That Allows Boys with Duchenne Muscular Dystrophy To Remain Walking.
Tue Dec 10, 2013
Headache Pictures Slideshow: A Visual Guide to Migraine Headaches
A migraine is a throbbing painful headache, usually on one side of the head, that is often initiated or "triggered" by specific compounds or situations .
Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
"We have achieved a number of important and transformational milestones. In addition to robust growth of NUEDEXTA for PBA, we formed a co-promote partnership with Merck which will leverage our commercial leadership in the institutional setting.
Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R)...
Zogenix, Inc. , a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today that the U.S. Food and Drug Administration has approved the supplemental New Drug Application for a 4 mg dose of SUMAVEL DosePro Needle-free Delivery System.
Fri Dec 06, 2013
New Report Available: MAP Pharmaceuticals, Inc. - Pharmaceuticals &...
It focuses on the development and commercialization of novel therapies in the field of neurology.